WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...
A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback